10x Genomics, Inc. (TXG)

On our desk, the reaction to the Q2 2026 print was overwhelmingly constructive. Seeing 10x Genomics beat consensus EPS expectations (reporting a loss of 14c vs. 2c consensus) while simultaneously bumping their 2026 revenue guidance up to a range of $610M to $630M gave the Street permission to re-rate the name. With multiple sell-side shops like Canaccord, Stifel, and Citi pushing targets up toward the $50-$60 range, the momentum has been institutional-backed. However, looking closely at the filings, adjusting for lumpy non-recurring litigation settlements shows underlying core operational growth hovering around 3%, which means valuation multiples demand flawless execution moving forward.

From a risk management standpoint, we are tracking the divergence between management's bullish commentary on order flow and the broader fundamental headwinds. While the balance sheet remains relatively sound, the projected annualized revenue growth of roughly 0.8% through 2026 represents a sharp deceleration from their historical 7.5% five-year pace. Furthermore, operating expenses expanded significantly year-over-year due to lower settlement gains compared to the second quarter of 2025, pushing net losses back into negative territory at $17.9 million. We remain cautious regarding how much multiple expansion is justified given the slower top-line growth trajectory.

In our clinical and translational research workflow, platform adoption remains heavily anchored on robust single-cell and spatial biology tools, and the recent research collaboration with Lausanne University Hospital highlights continued institutional validation. That said, when evaluating workflows against competing technologies, researchers are increasingly cost-conscious. Even with lower manufacturing costs and tariff refunds helping 10x lift their gross margins to 74% in Q2, the pricing pressure on consumables and instrumentation remains a persistent tactical hurdle in lab budget allocations.

Watching the recent price action, TXG staged a sharp 14.10% single-session surge following the early August earnings release, accompanied by strong relative volume around 1.6x. Consensus sentiment is heavily split between medium-term hold recommendations (56% of 16 analyst ratings) and aggressive bull-case price target hikes from firms like Leerink and TD Cowen. Traders need to account for this polarized sentiment; while short-term momentum is clearly favoring the bulls after breaking out of past lows, longer-term fundamentalists are wary of ballooning per-share loss projections for the upcoming year.